Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. [artículo]
Por: Ciruelos Gil, Eva María [Oncología Médica]
.
Colaborador(es): Servicio de Oncología Médica.
Tipo de material: 
ArtículoEditor: The Lancet. Oncology, 2014Descripción: 15(11):1269-78.Recursos en línea: Solicitar documentol Resumen: Combining bevacizumab with first-line or second-line chemotherapy improves progression-free survival in HER2-negative locally recurrent or metastatic breast cancer. We assessed the efficacy and safety of further bevacizumab therapy in patients with locally recurrent or metastatic breast cancer whose disease had progressed after treatment with bevacizumab plus chemotherapy.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC15927 (Navegar estantería) | Disponible |
Formato Vancouver:
Von Minckwitz G, Puglisi F, Cortés J, Vrdoljak E, Marschner N, Zielinski C et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78.
PMID: 25273342
Contiene 20 referencias
Combining bevacizumab with first-line or second-line chemotherapy improves progression-free survival in HER2-negative locally recurrent or metastatic breast cancer. We assessed the efficacy and safety of further bevacizumab therapy in patients with locally recurrent or metastatic breast cancer whose disease had progressed after treatment with bevacizumab plus chemotherapy.
No hay comentarios para este ejemplar.